PE20110805A1 - Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso - Google Patents
Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de usoInfo
- Publication number
- PE20110805A1 PE20110805A1 PE2011000606A PE2011000606A PE20110805A1 PE 20110805 A1 PE20110805 A1 PE 20110805A1 PE 2011000606 A PE2011000606 A PE 2011000606A PE 2011000606 A PE2011000606 A PE 2011000606A PE 20110805 A1 PE20110805 A1 PE 20110805A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- spiro
- beta
- secretases
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I, DONDE A1 ES CR6, N; A2 ES CR5, N; A3 ES CR4, N; A5 ES CR1, N; A6 ES CR8, N; T1 ES CR2, N; T2 ES CR7, N; R1, R4, R5 Y R8 SON CADA UNO H, F, Cl, Br, CF3, OCF3, ALQUILO C1-C6, ENTRE OTROS; R2 Y R7 SON CADA UNO H, HALO, HALOALQUILO HALOALCOXILO,ALQUINILO C1-C6, ENTRE OTROS; R3 Y R6 SON CADA UNO HALO, HALOALQUILO, CN, OH, O(ALQUILO C1-C6), CO-(ALQUILO C1-C6), ENTRE OTROS; W ES R1R1; X ES O, S; Y ESTA AUSENTE O ES CR1R1, C(=O), O, NR1, ENTRE OTROS; Z ESTA AUSENTE O ES CR1R1, C(=O), O, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(2,2-DIMETILPROPOXI)-7'-(5-PIRIMIDINIL)ESPIRO[1,3-OXAZOL-4,9'-XANTEN]-2-AMINA; (4R)-2'-PROPOXI-7'-(5-PIRIMIDINIL)ESPIRO[1,3-OXAZOL-4,9-XANTEN]-2-AMINA; (4R)-2'-(3,3-DIMETIL-1-BUTIN-1-IL)-7'-(5-PIRIMIDINIL)ESPIRO[1,3-OXAZOL-4,9'-XANTEN]-2-AMINA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE BETA SECRETASA SIENDO UTILES EN EL TRATAMIENTO DE ALZHEIMER, DETERIORO COGNITIVO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9608208P | 2008-09-11 | 2008-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110805A1 true PE20110805A1 (es) | 2011-11-09 |
Family
ID=41319591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011000606A PE20110805A1 (es) | 2008-09-11 | 2009-09-11 | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso |
Country Status (21)
Country | Link |
---|---|
US (1) | US8426447B2 (es) |
EP (1) | EP2328903B1 (es) |
JP (1) | JP5579720B2 (es) |
KR (1) | KR20110073511A (es) |
CN (1) | CN102209721A (es) |
AU (1) | AU2009291602B2 (es) |
BR (1) | BRPI0918449A2 (es) |
CA (1) | CA2736130C (es) |
CL (1) | CL2011000516A1 (es) |
CO (1) | CO6362014A2 (es) |
CR (1) | CR20110134A (es) |
EA (1) | EA201100461A1 (es) |
ES (1) | ES2459195T3 (es) |
IL (1) | IL211440A0 (es) |
MA (1) | MA32705B1 (es) |
MX (1) | MX2011002705A (es) |
MY (1) | MY148558A (es) |
PE (1) | PE20110805A1 (es) |
TW (1) | TWI385175B (es) |
WO (1) | WO2010030954A1 (es) |
ZA (1) | ZA201102674B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
NZ594230A (en) | 2009-03-13 | 2013-11-29 | Vitae Pharmaceuticals Inc | Inhibitors of beta-secretase |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
EP2539322B1 (en) | 2010-02-24 | 2014-01-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
AU2011227511B2 (en) * | 2010-03-15 | 2014-02-20 | Amgen Inc. | Spiro-tetracyclic ring compounds as Beta - secretase modulators |
JP5584352B2 (ja) * | 2010-03-15 | 2014-09-03 | アムジエン・インコーポレーテツド | β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途 |
WO2011130741A1 (en) * | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
EP2601197B1 (en) * | 2010-08-05 | 2014-06-25 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
WO2012027261A1 (en) | 2010-08-23 | 2012-03-01 | Amgen Inc. | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes |
AR083953A1 (es) * | 2010-11-22 | 2013-04-10 | Array Biopharma Inc | Compuestos para tratar enfermedades neurodegenerativas |
EP2644607A4 (en) | 2010-11-22 | 2014-05-28 | Idemitsu Kosan Co | OXYGENIC FUSIONED RING DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT THEREWITH |
EP2643325A1 (en) | 2010-11-23 | 2013-10-02 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
US9346827B2 (en) | 2011-02-07 | 2016-05-24 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use |
WO2012112462A1 (en) | 2011-02-15 | 2012-08-23 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2012138590A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
EP2718287A1 (en) | 2011-06-07 | 2014-04-16 | F.Hoffmann-La Roche Ag | [1,3]oxazines |
EP2747769B1 (en) | 2011-08-22 | 2017-08-02 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
WO2013044092A1 (en) * | 2011-09-21 | 2013-03-28 | Amgen Inc. | Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
WO2013054108A1 (en) * | 2011-10-10 | 2013-04-18 | Astrazeneca Ab | Mono-fluoro beta-secretase inhibitors |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
EP2650284A1 (en) * | 2012-04-10 | 2013-10-16 | Merz Pharma GmbH & Co. KGaA | Heterocyclic derivatives as metabotropic glutamate receptor modulators |
AR091203A1 (es) | 2012-05-30 | 2015-01-21 | Astellas Pharma Inc | Compuestos de cromano |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000182B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US10548882B2 (en) | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
US9290477B2 (en) | 2012-09-28 | 2016-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of β-secretase |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
AU2016215431B2 (en) | 2015-02-02 | 2020-07-23 | Valo Early Discovery, Inc. | 3-aryl-4-amido-bicyclic (4,5,0) hydroxamic acids as HDAC inhibitors |
US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2683718A (en) * | 1952-01-11 | 1954-07-13 | Searle & Co | Spiro-[xanthene-9, 4'-imidazolidine]-2, 5-dione |
US3185696A (en) * | 1959-03-12 | 1965-05-25 | Jack M Tien | 3', 6'-diaminofluoran derivatives of gamma-lactam |
FR2576178B1 (fr) | 1985-01-24 | 1987-04-17 | Furodet Philippe | Procede de fabrication pour un enfumoir a chargement par-dessous |
DE3601492A1 (de) | 1986-01-20 | 1987-07-23 | Vacuumschmelze Gmbh | Verfahren zur herstellung eines stabilisierten filament-supraleiters mit hohem anteil an stabilisierungsmaterial |
US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
SI9300303A (en) * | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
EP0871720A2 (en) * | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
CN1502692A (zh) * | 1998-09-24 | 2004-06-09 | �������Ŷ���Լ��������˾ | 阿尔茨海默氏疾病分泌酶 |
MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
ES2248356T3 (es) * | 2000-06-30 | 2006-03-16 | Elan Pharmaceuticals, Inc. | Compuestos para tratar la enfermedad de alzheimer. |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
BR0210721A (pt) * | 2001-06-27 | 2004-07-20 | Elan Pharm Inc | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição |
KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
JP2004538274A (ja) * | 2001-07-10 | 2004-12-24 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病を治療するためのα−ヒドロキシアミドスタチン誘導体 |
BR0211118A (pt) * | 2001-07-10 | 2004-10-26 | Elan Pharm Inc | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal |
US20030109559A1 (en) * | 2001-07-11 | 2003-06-12 | Andrea Gailunas | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds |
CA2462851A1 (en) * | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
JP2005508940A (ja) | 2001-10-05 | 2005-04-07 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病の治療に有用なアリルアミド |
BR0213743A (pt) * | 2001-10-29 | 2004-12-21 | Upjohn Co | Métodos de tratar ou prevenir mal de alzheimer e uma doença, de tratar um indivìduo que tenha, ou de prevenir que um indivìduo contraia, uma doença ou condição, de inibir a atividade de beta-secretase, a clivagem de um isótipo de protéina precursora de amilóide e a produção de peptìdeo beta amilóide e de placa beta-amilóide em um animal e de produzir um complexo de beta-secretase, uso de um composto e composição |
NZ533107A (en) * | 2001-11-08 | 2007-04-27 | Upjohn Co | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
TW200304374A (en) * | 2001-11-30 | 2003-10-01 | Smithkline Beecham Plc | Novel compounds |
MXPA04005428A (es) * | 2001-12-06 | 2004-12-06 | Elan Pharm Inc | Hidroxietilaminas substituidas. |
AU2003206413A1 (en) * | 2002-01-04 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Substituted amino carboxamides for the treatment of alzheimer's disease |
WO2003062209A2 (en) * | 2002-01-17 | 2003-07-31 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
AU2003276047A1 (en) * | 2002-06-17 | 2003-12-31 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
US7115652B2 (en) * | 2002-06-17 | 2006-10-03 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
PL374999A1 (en) | 2002-06-20 | 2005-11-14 | Pharmacia & Upjohn Company Llc | Process for preparing 5-(1, 3-oxazol-2-yl) benzoic acid derivatives |
UY27967A1 (es) * | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
ATE443043T1 (de) * | 2002-11-12 | 2009-10-15 | Merck & Co Inc | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer |
GB0228410D0 (en) * | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
AU2004204692B2 (en) * | 2003-01-07 | 2009-07-09 | Merck & Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of Alzheimer's disease |
GB0305918D0 (en) * | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
RU2005131845A (ru) * | 2003-03-14 | 2006-02-10 | Мерк Шарп энд Домэ Лимитед (GB) | Способ лечения легкого ухудшения познавательной способности и предотвращения или задержки начала болезни альцгеймера |
AR044044A1 (es) * | 2003-04-21 | 2005-08-24 | Elan Pharm Inc | 2-hidroxi-3-diaminoalcanos de benzamida |
BRPI0409627A (pt) * | 2003-04-21 | 2006-04-25 | Elan Pharm Inc | 2-hidróxi-3-diaminoalcanos de fenacila |
CA2529994A1 (en) * | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
CA2530006A1 (en) * | 2003-07-01 | 2005-01-20 | Merck & Co., Inc. | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
US7700603B2 (en) * | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7763609B2 (en) * | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
PL1699455T3 (pl) | 2003-12-15 | 2013-10-31 | Merck Sharp & Dohme | Heterocykliczne inhibitory proteaz aspartylowych |
GB0402143D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
WO2005097767A1 (en) | 2004-03-30 | 2005-10-20 | Merck & Co., Inc. | 2-aminothiazole compounds useful as aspartyl protease inhibitors |
PE20060459A1 (es) * | 2004-06-16 | 2006-05-30 | Wyeth Corp | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA |
US20090221579A1 (en) | 2004-10-15 | 2009-09-03 | Jeffrey Scott Albert | Substituted Amino-Compounds and Uses Thereof |
CN101103034A (zh) | 2005-01-14 | 2008-01-09 | 惠氏公司 | 抑制β-分泌酶的氨基-咪唑酮 |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
WO2006138230A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of protease inhibitors |
KR20080028881A (ko) | 2005-06-14 | 2008-04-02 | 쉐링 코포레이션 | 헤테로사이클릭 아스파르틸 프로테아제 억제제, 이의제조방법 및 용도 |
WO2006138528A2 (en) * | 2005-06-16 | 2006-12-28 | Janssen Pharmaceutica N.V | Tricyclic opioid modulators |
TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
WO2007009014A2 (en) * | 2005-07-13 | 2007-01-18 | Raviv Laor | Personal topical disinfectant device |
WO2007011833A2 (en) | 2005-07-18 | 2007-01-25 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
EP2256107A1 (en) * | 2005-09-26 | 2010-12-01 | Wyeth LLC | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE) |
ES2476027T3 (es) * | 2005-10-25 | 2014-07-11 | Shionogi & Co., Ltd. | Derivados de aminodihidrotriazina |
WO2007100536A1 (en) * | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
WO2007114771A1 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR TREATING OR PREVENTING Aβ-RELATED PATHOLOGIES |
TW200808751A (en) | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
EP2032542A2 (en) * | 2006-06-12 | 2009-03-11 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
EP2091328B1 (en) | 2006-10-30 | 2011-12-28 | Merck Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
KR101174191B1 (ko) | 2007-02-02 | 2012-08-14 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료용 taar1 리간드로서 2-아미노옥사졸린 |
PE20090617A1 (es) | 2007-03-23 | 2009-05-08 | Wyeth Corp | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa |
WO2008133273A1 (ja) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
ES2476605T3 (es) * | 2007-04-24 | 2014-07-15 | Shionogi & Co., Ltd. | Derivados de aminohidrotiazina sustituidos con grupos cíclicos |
TW200902503A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
PE20091438A1 (es) * | 2008-01-18 | 2009-09-26 | Eisai Randd Man Co Ltd | Derivados fusionados de aminodihidrotiazina |
CN101952260B (zh) * | 2008-02-18 | 2013-02-13 | 弗·哈夫曼-拉罗切有限公司 | 4,5-二氢-*唑-2-基胺衍生物 |
TW200948364A (en) | 2008-04-22 | 2009-12-01 | Schering Corp | Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Bace抑制劑 |
CA2728480A1 (en) | 2008-07-24 | 2010-01-28 | F. Hoffmann-La Roche Ag | 4,5-dihydro-oxazol-2-yl derivatives |
EP2318416B1 (en) * | 2008-07-28 | 2013-09-04 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
-
2009
- 2009-09-11 BR BRPI0918449A patent/BRPI0918449A2/pt not_active IP Right Cessation
- 2009-09-11 MY MYPI2011001092A patent/MY148558A/en unknown
- 2009-09-11 PE PE2011000606A patent/PE20110805A1/es not_active Application Discontinuation
- 2009-09-11 AU AU2009291602A patent/AU2009291602B2/en not_active Ceased
- 2009-09-11 KR KR1020117008316A patent/KR20110073511A/ko not_active Application Discontinuation
- 2009-09-11 MX MX2011002705A patent/MX2011002705A/es active IP Right Grant
- 2009-09-11 EP EP09737222.1A patent/EP2328903B1/en active Active
- 2009-09-11 WO PCT/US2009/056748 patent/WO2010030954A1/en active Application Filing
- 2009-09-11 CN CN2009801456428A patent/CN102209721A/zh active Pending
- 2009-09-11 TW TW098130795A patent/TWI385175B/zh not_active IP Right Cessation
- 2009-09-11 EA EA201100461A patent/EA201100461A1/ru unknown
- 2009-09-11 CA CA2736130A patent/CA2736130C/en not_active Expired - Fee Related
- 2009-09-11 US US12/558,426 patent/US8426447B2/en active Active
- 2009-09-11 ES ES09737222.1T patent/ES2459195T3/es active Active
- 2009-09-11 JP JP2011527012A patent/JP5579720B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-27 IL IL211440A patent/IL211440A0/en unknown
- 2011-03-10 CL CL2011000516A patent/CL2011000516A1/es unknown
- 2011-03-14 CR CR20110134A patent/CR20110134A/es unknown
- 2011-03-25 CO CO11036742A patent/CO6362014A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02674A patent/ZA201102674B/en unknown
- 2011-04-11 MA MA33762A patent/MA32705B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
IL211440A0 (en) | 2011-05-31 |
MA32705B1 (fr) | 2011-10-02 |
US8426447B2 (en) | 2013-04-23 |
TWI385175B (zh) | 2013-02-11 |
CL2011000516A1 (es) | 2011-08-26 |
US20100087429A1 (en) | 2010-04-08 |
MX2011002705A (es) | 2011-09-09 |
AU2009291602B2 (en) | 2013-02-14 |
CN102209721A (zh) | 2011-10-05 |
CR20110134A (es) | 2011-08-04 |
EA201100461A1 (ru) | 2011-10-31 |
MY148558A (en) | 2013-04-30 |
EP2328903B1 (en) | 2014-03-05 |
BRPI0918449A2 (pt) | 2019-09-24 |
AU2009291602A1 (en) | 2010-03-18 |
CA2736130A1 (en) | 2010-03-18 |
WO2010030954A1 (en) | 2010-03-18 |
CO6362014A2 (es) | 2012-01-20 |
ZA201102674B (en) | 2011-12-28 |
CA2736130C (en) | 2014-01-14 |
JP2012502112A (ja) | 2012-01-26 |
EP2328903A1 (en) | 2011-06-08 |
JP5579720B2 (ja) | 2014-08-27 |
TW201022280A (en) | 2010-06-16 |
KR20110073511A (ko) | 2011-06-29 |
ES2459195T3 (es) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110805A1 (es) | Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso | |
PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
CL2009000860A1 (es) | Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer. | |
AR084507A1 (es) | Derivados de indazoliltriazol | |
UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
PE20110383A1 (es) | Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a) | |
PE20130395A1 (es) | Pirazolo[1,5-a]pirimidinas para tratamiento antiviral | |
CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
PE20201165A1 (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
ECSP10010722A (es) | Compuestos orgánicos | |
AR085903A1 (es) | Compuestos de pirazol sustituidos con halogeno | |
AR070136A1 (es) | Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa | |
AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
PE20081700A1 (es) | Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico | |
CL2008002247A1 (es) | Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros. | |
TW200716529A (en) | New compounds II | |
MX2011007663A (es) | Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2. | |
UY28737A1 (es) | Compuestos farmacéuticamente activos | |
CL2009000404A1 (es) | Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras. | |
UY32409A (es) | Compuesto de anillo fusionado y su uso | |
CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. | |
ECSP13012664A (es) | Formas cristalinas de la sal clorhidrato de (4a-r,9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1h-inden[2,1-b]piridin-6-carbonitrilo y su uso como inhibidores de hsd 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |